[{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Kurt Alex Schalper<\/i><\/u><\/presenter>. Yale University, New Haven, CT","CSlideId":"","ControlKey":"c14045d9-ae68-4449-ac37-7c4505e34f82","ControlNumber":"9292","DisclosureBlock":"","End":"4\/10\/2022 3:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"20715","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Kurt Schalper, MD;PhD","PresenterKey":"869d2446-515c-4e14-9174-2010d2acf997","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Chairperson","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chairperson","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Benedito A. Carneiro<\/i><\/u><\/presenter>. Brown University, Providence, RI","CSlideId":"","ControlKey":"a0a247be-9da7-42eb-b5e9-2fbf0c1c52ef","ControlNumber":"9294","DisclosureBlock":"","End":"4\/10\/2022 3:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"20717","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Benedito Carneiro, MD;MS","PresenterKey":"51b3b939-e2b7-481f-ab16-ab2e5e8eb35a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Chairperson","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chairperson","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Kurt Alex Schalper<\/i><\/u><\/presenter>. Yale University, New Haven, CT","CSlideId":"","ControlKey":"d57c7d4a-3ff2-4913-89a3-6cc87d615c68","ControlNumber":"9293","DisclosureBlock":"","End":"4\/10\/2022 3:05:00 PM","HasWebcast":null,"Highlights":[],"Id":"20716","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Kurt Schalper, MD;PhD","PresenterKey":"869d2446-515c-4e14-9174-2010d2acf997","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Introduction","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Introduction","Topics":null,"cSlideId":""},{"Abstract":"Context: Polymerase epsilon (<i>POLE<\/i>) gene missense hotspot mutations can generate pathogenic (p) proofreading defects resulting in hypermutated genomic profiles.<br \/>Aim: Determine the prevalence, genomic consequences and immunotherapy sensitivity of advanced <i>POLE<\/i> mutated tumors according to mutation site, primary tumor and tumor mutational burden (TMB).<br \/>Results: Pan-Cancer TCGA &#38; MSKCC databases genomic analyses found a prevalence of non-pathogenic POLE mutations (POLEnp) of 3.4% with median TMB of 11 mutations\/Megabase (mt\/Mb, IQR 3-34). Pathogenic POLE mutations (POLEp) prevalence was 0.4% with median TMB of 215 mt\/Mb (IQR 107-324), predominantly in colorectal and endometrial cancers. Prevalence dropped to 0.1% in metastatic cancers. We assessed prospectively the efficacy of PD-1 blockade in mismatch repair proficient advanced solid tumors harboring <i>POLE <\/i>missense<i> <\/i>mutations (phase II ASCe Nivolumab trial; NCT03012581). Variants were categorized prospectively by a molecular board as POLEp, POLEnp or Variants with Unknown significance (VUS). The primary endpoint was the Overall Response Rate (ORR) at 12 weeks according to RECIST 1.1, and secondary endpoints included survival analyses according to POLE variants pathogenicity. Among 61 screened patients, 21 were eligible and 20 received Nivolumab and 19 were assessable for response (table 1). The 12-week ORR was 37% for patients harboring POLEp and VUS and resulted in major survival improvement compared to POLEnp patients (HR=0.1 ; CI95% 0.02-0.7); see results in Table 1. Among patients POLEp tumors, while higher TMB was not predictive of response, higher proportion of POLE-related mutational signature correlated with improved benefit. In silico exonucleasic POLE domain analyses confirmed that all POLEp and 2 VUS clustered in the DNA binding or the Catalytic site. Recategorizing the VUS according to the location within the exonucleasic domain improved the prediction of survival outcomes.<br \/>Impact: This study gives new insights on how DNA repair defects, mutational burden and signatures sensitize to PD-1 blockade and may offer emerging tumor agnostic biomarkers for benefit to checkpoint blockade.<table class=\"AbstractTable\" id=\"{7DC89C54-BC52-42F3-82F7-30FF64640790}\"><caption class=\"AbstractTableCaption\"><\/caption><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"3\"><b>POLE variant pathogenicity<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b>All<\/b><b>(N=21)<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>POLEnp<\/b><b>(N=5)<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>VUS<\/b><b>(N=4)<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>POLEp<\/b><b>(N=12)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Age, years &#177; SD<\/i><\/td><td rowspan=\"1\" colspan=\"1\">57 &#177; 16<\/td><td rowspan=\"1\" colspan=\"1\">64 &#177; 10<\/td><td rowspan=\"1\" colspan=\"1\">56 &#177; 16<\/td><td rowspan=\"1\" colspan=\"1\">54 &#177; 17<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Sex, Male (%)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">12 (57)<\/td><td rowspan=\"1\" colspan=\"1\">5 (100)<\/td><td rowspan=\"1\" colspan=\"1\">2 (50)<\/td><td rowspan=\"1\" colspan=\"1\">5 (42)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>PS (ECOG)=1 (%)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">16 (75)<\/td><td rowspan=\"1\" colspan=\"1\">4 (80)<\/td><td rowspan=\"1\" colspan=\"1\">2 (50)<\/td><td rowspan=\"1\" colspan=\"1\">10 (83)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"5\"><i>Primary tumor<\/i><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Colorectal<\/i><\/td><td rowspan=\"1\" colspan=\"1\">9 (43)<\/td><td rowspan=\"1\" colspan=\"1\">2 (40)<\/td><td rowspan=\"1\" colspan=\"1\">2 (50)<\/td><td rowspan=\"1\" colspan=\"1\">5 (42)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Endometrial<\/i><\/td><td rowspan=\"1\" colspan=\"1\">6 (29)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><td rowspan=\"1\" colspan=\"1\">6 (50)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Gastric<\/i><\/td><td rowspan=\"1\" colspan=\"1\">2 (9)<\/td><td rowspan=\"1\" colspan=\"1\">2 (40)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Glial<\/i><\/td><td rowspan=\"1\" colspan=\"1\">1 (5)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><td rowspan=\"1\" colspan=\"1\">1 (8)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Biliary tract<\/i><\/td><td rowspan=\"1\" colspan=\"1\">1 (5)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><td rowspan=\"1\" colspan=\"1\">1 (25)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Pancreas<\/i><\/td><td rowspan=\"1\" colspan=\"1\">2 (9)<\/td><td rowspan=\"1\" colspan=\"1\">1 (20)<\/td><td rowspan=\"1\" colspan=\"1\">1 (25)<\/td><td rowspan=\"1\" colspan=\"1\">0 (0)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Number of previous treatments<\/i><\/td><td rowspan=\"1\" colspan=\"1\">2.4 &#177; 2<\/td><td rowspan=\"1\" colspan=\"1\">5 &#177; 2<\/td><td rowspan=\"1\" colspan=\"1\">1.8 &#177; 1<\/td><td rowspan=\"1\" colspan=\"1\">1.5 &#177; 1<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>TMB (mt\/Mb, Min-Max)<\/i><i>(N=16)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">36.2 (2-385)<\/td><td rowspan=\"1\" colspan=\"1\">5 (4-9)<\/td><td rowspan=\"1\" colspan=\"1\">3 (2-4)<\/td><td rowspan=\"1\" colspan=\"1\">114 (25-385)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>ORR at 12 weeks (CR+PR)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">37%(N=7\/19)<\/td><td rowspan=\"1\" colspan=\"1\">0%(N=0\/5)<\/td><td rowspan=\"1\" colspan=\"1\">50%(N=2\/4)<\/td><td rowspan=\"1\" colspan=\"1\">46%(5\/10)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>DCR at 12 weeks (CR+PR+SD)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">58%(N=11\/19)<\/td><td rowspan=\"1\" colspan=\"1\">0%(N=0\/5)<\/td><td rowspan=\"1\" colspan=\"1\">75%(N=3\/4)<\/td><td rowspan=\"1\" colspan=\"1\">80%(8\/10)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Median Progresssion-Free survival (months)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">5.6<\/td><td rowspan=\"1\" colspan=\"1\">2.3<\/td><td rowspan=\"1\" colspan=\"2\">10.3vs POLEnp: <b>HR=0.2 IC95% 0.1-0.7<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><i>Median Overall Survival (months)<\/i><\/td><td rowspan=\"1\" colspan=\"1\">9.1<\/td><td rowspan=\"1\" colspan=\"1\">5.0<\/td><td rowspan=\"1\" colspan=\"2\">Not Reachedvs POLEnp:<b>HR=0.1 IC95% 0.02-0.7<\/b><\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT02-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Immuno-oncology,DNA repair,Tumor mutational burden,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Benoît Rousseau<\/i><\/u><\/presenter>, <presenter><i>Ivan Bieche<\/i><\/presenter>, <presenter><i>Eric Pasmant<\/i><\/presenter>, <presenter><i>Nadim Hamzaoui<\/i><\/presenter>, <presenter><i>Nicolas Leulliot<\/i><\/presenter>, <presenter><i>Lucas Michon<\/i><\/presenter>, <presenter><i>Aurelien De Reynies<\/i><\/presenter>, <presenter><i>Mike Foote<\/i><\/presenter>, <presenter><i>Julien Masliah-Planchon<\/i><\/presenter>, <presenter><i>Magali Svrcek<\/i><\/presenter>, <presenter><i>Romain Cohen<\/i><\/presenter>, <presenter><i>Victor Simmet<\/i><\/presenter>, <presenter><i>Paule Augereau<\/i><\/presenter>, <presenter><i>David Malka<\/i><\/presenter>, <presenter><i>Antoine Hollebecque<\/i><\/presenter>, <presenter><i>Damien Pouessel<\/i><\/presenter>, <presenter><i>Carlos Gomez-Roca<\/i><\/presenter>, <presenter><i>Rosine Guimbaud<\/i><\/presenter>, <presenter><i>Amandine Bruyas<\/i><\/presenter>, <presenter><i>Marielle Guillet<\/i><\/presenter>, <presenter><i>Muriel Duluc<\/i><\/presenter>, <presenter><i>Sophie Cousin<\/i><\/presenter>, <presenter><i>Christelle De la Fourchardiere<\/i><\/presenter>, <presenter><i>Frederic Rolland<\/i><\/presenter>, <presenter><i>Sandrine Hiret<\/i><\/presenter>, <presenter><i>Esma Saada-Bouzid<\/i><\/presenter>, <presenter><i>Olivier Bouche<\/i><\/presenter>, <presenter><i>Thierry Andre<\/i><\/presenter>, <presenter><i>Diane Pannier<\/i><\/presenter>, <presenter><i>Farid El Hajbi<\/i><\/presenter>, <presenter><i>Stephane Oudard<\/i><\/presenter>, <presenter><i>Christophe Tournigand<\/i><\/presenter>, <presenter><i>Jean-Charles Soria<\/i><\/presenter>, <presenter><i>Drew Gerber<\/i><\/presenter>, <presenter><i>Dennis Stephens<\/i><\/presenter>, <presenter><i>Michelle Lamandola-Essel<\/i><\/presenter>, <presenter><i>Steven B Maron<\/i><\/presenter>, <presenter><i>Bill Diplas<\/i><\/presenter>, <presenter><i>Guillem Argiles<\/i><\/presenter>, <presenter><i>Asha Krishnan<\/i><\/presenter>, <presenter><i>Neil Segal<\/i><\/presenter>, <presenter><i>Andrea Cercek<\/i><\/presenter>, <presenter><i>Nathalie Hoog-Labouret<\/i><\/presenter>, <presenter><i>Frederic Legrand<\/i><\/presenter>, <presenter><i>Clotide Simon<\/i><\/presenter>, <presenter><i>Assia Lamrani-Ghaouti<\/i><\/presenter>, <presenter><i>Luis A. Diaz Jr.<\/i><\/presenter>, <presenter><i>Pierre Saintigny<\/i><\/presenter>, <presenter><i>Sylvie Chevret<\/i><\/presenter>, <presenter><i>Aurelien Marabelle<\/i><\/presenter>. Memorial Sloan Kettering Cancer Center, New York, NY, Institut Curie, Paris, France, Service de Génétique et Biologie Moléculaires, Hôpital Cochin, Paris, France, Cibles Thérapeutiques et Conception de Médicaments, CNRS UMR8015, Université de Paris, UFR de Pharmacie de Paris, Paris, France, Department of Translational Medicine, Centre Léon Bérard, Lyon, France, Hopital Saint Antoine, Paris, France, Institut de Cancérologie de l'Ouest, Angers, France, Institut Gustave Roussy, Villejuif, France, Institut Claudius Regaud \/ IUCT Oncopole, Toulouse, France, Hôpital de la Croix-Rousse, Lyon, France, Hopital de la Timone, Marseille, France, Institut Bergonie, Bordeaux, France, Centre Leon Berard, Lyon, France, Institut de Cancérologie de l'Ouest, Saint-Herblain, France, Centre Antoine Lacassagne, Nice, France, CHU de Reims, Reims, France, Centre Oscar Lambret, Lille, France, Hopital Europeen Georges Pompidou, Paris, France, Hopital Henri Mondor, Creteil, France, Institut National du Cancer, Boulogne-Billancourt, France, UNICANCER, Paris, France, Centre Léon Bérard, Lyon, France, Hopital Saint Louis, Paris, France","CSlideId":"","ControlKey":"27724ff8-97f1-4342-9644-ebf24ecfe212","ControlNumber":"7870","DisclosureBlock":"&nbsp;<b>B. Rousseau, <\/b> None..<br><b>I. Bieche, <\/b> None..<br><b>E. Pasmant, <\/b> None..<br><b>N. Hamzaoui, <\/b> None..<br><b>N. Leulliot, <\/b> None..<br><b>L. Michon, <\/b> None..<br><b>A. de Reynies, <\/b> None..<br><b>M. Foote, <\/b> None..<br><b>J. Masliah-Planchon, <\/b> None..<br><b>M. Svrcek, <\/b> None.&nbsp;<br><b>R. Cohen, <\/b> <br><b>Servier<\/b> Independent Contractor. <br><b>Amgen<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>V. Simmet, <\/b> <br><b>Lilly<\/b> Independent Contractor. <br><b>Servier<\/b> Independent Contractor. <br><b>Amgen<\/b> Travel. <br><b>Novartis<\/b> Travel.<br><b>P. Augereau, <\/b> None.&nbsp;<br><b>D. Malka, <\/b> <br><b>Amgen<\/b> Independent Contractor. <br><b>Agios<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>HalioDx<\/b> Independent Contractor. <br><b>Merck Serono<\/b> Independent Contractor. <br><b>MSD<\/b> Independent Contractor. <br><b>Pierre Fabre<\/b> Independent Contractor. <br><b>Roche<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>Sanofi<\/b> Independent Contractor. <br><b>Servier<\/b> Independent Contractor. <br><b>Viatris<\/b> Independent Contractor.<br><b>A. Hollebecque, <\/b> None.&nbsp;<br><b>D. Pouessel, <\/b> <br><b>Ipsen<\/b> Independent Contractor. <br><b>Ipsen<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor. <br><b>Astrazeneca<\/b> Independent Contractor. <br><b>Sanofi<\/b> Travel. <br><b>Pfizer<\/b> Travel. <br><b>Merck<\/b> Independent Contractor. <br><b>Astellas<\/b> Independent Contractor. <br><b>Janssen<\/b> Independent Contractor. <br><b>C. Gomez-Roca, <\/b> <br><b>Pierre Fabire<\/b> Independent Contractor, Travel. <br><b>Genentech<\/b> Travel. <br><b>BMS<\/b> Independent Contractor, Travel. <br><b>Eisai<\/b> Independent Contractor. <br><b>Foundation Medicine<\/b> Independent Contractor.<br><b>R. Guimbaud, <\/b> None.&nbsp;<br><b>A. Bruyas, <\/b> <br><b>BMS<\/b> Independent Contractor.<br><b>M. Guillet, <\/b> None..<br><b>M. Duluc, <\/b> None..<br><b>S. Cousin, <\/b> None..<br><b>C. de la Fourchardiere, <\/b> None.&nbsp;<br><b>F. Rolland, <\/b> <br><b>Merck<\/b> Independent Contractor. <br><b>MSD<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor.<br><b>S. Hiret, <\/b> None.&nbsp;<br><b>E. Saada-Bouzid, <\/b> <br><b>Merck<\/b> Independent Contractor. <br><b>MSD<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor. <br><b>O. Bouche, <\/b> <br><b>Merck<\/b> Independent Contractor. <br><b>Roche<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>Astrazeneca<\/b> Independent Contractor. <br><b>MSD<\/b> Independent Contractor.<br><b>T. Andre, <\/b> None..<br><b>D. Pannier, <\/b> None..<br><b>F. El Hajbi, <\/b> None.&nbsp;<br><b>S. Oudard, <\/b> <br><b>Ipsen<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Janssen<\/b> Independent Contractor. <br><b>Astellas<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor. <br><b>Roche<\/b> Independent Contractor.<br><b>C. Tournigand, <\/b> None.&nbsp;<br><b>J. Soria, <\/b> <br><b>Gristone<\/b> Stock. <br><b>AstraZeneca<\/b> Stock. <br><b>Relay Therapeutics<\/b> Stock.<br><b>D. Gerber, <\/b> None..<br><b>D. Stephens, <\/b> None..<br><b>M. Lamandola-Essel, <\/b> None..<br><b>S. Maron, <\/b> None.&nbsp;<br><b>B. Diplas, <\/b> <br><b>Duke University<\/b> Patent.<br><b>G. Argiles, <\/b> None..<br><b>A. Krishnan, <\/b> None..<br><b>N. Segal, <\/b> None..<br><b>A. Cercek, <\/b> None..<br><b>N. Hoog-Labouret, <\/b> None..<br><b>F. Legrand, <\/b> None..<br><b>C. Simon, <\/b> None..<br><b>A. Lamrani-Ghaouti, <\/b> None.&nbsp;<br><b>L. A. Diaz, <\/b> <br><b>PGDx<\/b> Stock, Other, Board of director. <br><b>Jounce Therapeutics<\/b> Board of directors. <br><b>Neophore<\/b> Independent Contractor, Stock. <br><b>Delphi<\/b> Independent Contractor. <br><b>Kinnate<\/b> Independent Contractor. <br><b>Se'er<\/b> Independent Contractor. <br><b>Innovatus CP<\/b> Independent Contractor. <br><b>PetDx<\/b> Independent Contractor.<br><b>P. Saintigny, <\/b> None..<br><b>S. Chevret, <\/b> None.&nbsp;<br><b>A. Marabelle, <\/b> <br><b>Genentech\/Roche<\/b> Independent Contractor. <br><b>BMS<\/b> Independent Contractor. <br><b>MSD<\/b> Independent Contractor. <br><b>Lytix Pharma<\/b> Independent Contractor. <br><b>Eisai<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Novartis<\/b> Independent Contractor. <br><b>Chugai<\/b> Independent Contractor.","End":"4\/10\/2022 3:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"20159","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT021","PresenterBiography":null,"PresenterDisplayName":"Benoît Rousseau, MD;PhD","PresenterKey":"cadfe3c7-8cd3-47c0-b82f-6c3f383ac6ca","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT021. PD-1 blockade in solid tumors with defects in polymerase epsilon","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:05:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"PD-1 blockade in solid tumors with defects in polymerase epsilon","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"f44cecab-1934-452b-b460-afb46e78f2c1","ControlNumber":"9295","DisclosureBlock":"","End":"4\/10\/2022 3:20:00 PM","HasWebcast":null,"Highlights":[],"Id":"20718","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"High tumor mutational burden assessed in tissue biopsies (tTMB-H) or blood (bTMB-H) is associated with clinical efficacy in patients treated with immunotherapies. CheckMate 848 (NCT03668119) is a prospective phase 2 study of nivolumab (NIVO) with or without ipilimumab (IPI) in patients with advanced or metastatic solid tumors that are tTMB-H or bTMB-H (&#8805; 10 mutations\/megabase) who were immunotherapy-naive and refractory to standard local therapies.<br \/>The primary endpoint was objective response rate (ORR) in patients with tTMB-H or bTMB-H, assessed by FoundationOne<sup>&#174;<\/sup> CDx-based and Clinical Trial Assays (Foundation Medicine), respectively. The study was not powered to compare NIVO + IPI vs NIVO. We present the interim and final analyses for the tTMB-H and bTMB-H cohorts, respectively (&#8805; 12 months follow-up, database lock June 2021).<br \/>Of 1954 screened patients, 212 were randomized 2:1 to NIVO 240 mg Q2W + IPI 1 mg\/kg Q6W or NIVO 480 mg Q4W for &#8804; 24 months, and 201 (135 tTMB-H; 147 bTMB-H) were refractory to standard therapies. Of &#62; 40 tumor types, colorectal (10.8%), small-cell lung (7.5%), breast (7.1%), and uterine (7.1%) were the most common. ORR and survival outcomes with NIVO + IPI were improved in patients with tTMB-H. The responses were independent of bTMB-H status in the tTMB-H cohort but improved with tTMB-H status in the bTMB-H cohort (Table). The safety profile of NIVO + IPI was manageable, and clinical outcomes with NIVO were comparable with previous studies. The impact of TMB cutoff, PD-L1 expression, and microsatellite instability were explored.<br \/>In conclusion, NIVO + IPI demonstrated clinical efficacy with a manageable safety profile in patients with advanced or metastatic solid tumors that are tTMB-H or bTMB-H and refractory to standard therapies, with increased efficacy observed in patients with tTMB-H.<table class=\"AbstractTable\" id=\"{9F338CBF-D35D-49A7-ACE1-DBA502DA07AC}\"><caption class=\"AbstractTableCaption\"><\/caption><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"2\">NIVO + IPI<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b>tTMB-H cohort<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>bTMB-H cohort<sup>a<\/sup><\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Patients, n (%)<sup>b,c<\/sup><\/td><td rowspan=\"1\" colspan=\"1\">68 (32.1)<\/td><td rowspan=\"1\" colspan=\"1\">80 (37.7)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Number of prior treatments, median (range)<\/td><td rowspan=\"1\" colspan=\"1\">2 (0&#8211;7)<\/td><td rowspan=\"1\" colspan=\"1\">2 (1&#8211;9)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">ORR, n (%)<sup>c<\/sup>, 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">24 (35.3), 24.1&#8211;47.8<\/td><td rowspan=\"1\" colspan=\"1\">18 (22.5), 13.9&#8211;33.2<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">ORR in patients with bTMB-H by tTMB<sup>c<\/sup>:<\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#60; 10 mut\/Mb (n = 31), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><td rowspan=\"1\" colspan=\"1\">3 (9.7), 2.0&#8211;25.8<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8805; 10 mut\/Mb (n = 39), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><td rowspan=\"1\" colspan=\"1\">13 (33.3), 19.1&#8211;50.2<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8805; 10 to &#60; 16 mut\/Mb (n = 18), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><td rowspan=\"1\" colspan=\"1\">3 (16.7), 3.6&#8211;41.4<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8805; 16 mut\/Mb (n = 21), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><td rowspan=\"1\" colspan=\"1\">10 (47.6), 25.7&#8211;70.2<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">ORR in patients with tTMB-H by bTMB<sup>c<\/sup>:<\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#60; 10 mut\/Mb (n = 20), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">7 (35.0), 15.4&#8211;59.2<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8805; 10 mut\/Mb (n = 43), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">16 (37.2), 23.0&#8211;53.3<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8805; 10 to &#60; 16 mut\/Mb (n = 12), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">3 (25.0), 5.5&#8211;57.2<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">&#8805; 16 mut\/Mb (n = 31), n (%), 95% CI<\/td><td rowspan=\"1\" colspan=\"1\">13 (41.9), 24.5&#8211;60.9<\/td><td rowspan=\"1\" colspan=\"1\">NA<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Percentage of responders (&#8805; 9 months) (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">91 (68&#8211;98)<\/td><td rowspan=\"1\" colspan=\"1\">88 (61&#8211;97)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Median PFS, months (95% CI)<sup>c<\/sup><\/td><td rowspan=\"1\" colspan=\"1\">4.1 (2.8&#8211;11.3)<\/td><td rowspan=\"1\" colspan=\"1\">2.8 (2.3&#8211;3.0)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">Median OS, months (95% CI)<sup>c<\/sup><\/td><td rowspan=\"1\" colspan=\"1\">14.5 (7.7&#8211;NE)<\/td><td rowspan=\"1\" colspan=\"1\">8.5 (5.8&#8211;10.5)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"3\"><sup>a<\/sup>The bTMB cohort was randomized prior to December 20, 2019. <sup>b<\/sup>Out of 212 randomized patients; data presented in this table are from patients who were refractory to standard therapies.<sup> c<\/sup>Minimum follow-up 12 months. bTMB, blood tumor mutational burden; NA, not applicable; NE, not evaluable; PFS, progression-free survival; OS, overall survival; tTMB, tissue tumor mutational burden.<\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT02-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Tumor mutational burden,Solid tumors,Nivolumab + ipilimumab,Liquid biopsy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Michael Schenker<\/i><\/u><\/presenter>, <presenter><i>Mauricio Burotto<\/i><\/presenter>, <presenter><i>Martin Richardet<\/i><\/presenter>, <presenter><i>Tudor Ciuleanu<\/i><\/presenter>, <presenter><i>Anthony Goncalves<\/i><\/presenter>, <presenter><i>Neeltje Steeghs<\/i><\/presenter>, <presenter><i>Patrick Schöffski<\/i><\/presenter>, <presenter><i>Paolo A. Ascierto<\/i><\/presenter>, <presenter><i>Michele Maio<\/i><\/presenter>, <presenter><i>Iwona Lugowska<\/i><\/presenter>, <presenter><i>Lorena Lupinacci<\/i><\/presenter>, <presenter><i>Alexandra Leary<\/i><\/presenter>, <presenter><i>Jean-Pierre Delord<\/i><\/presenter>, <presenter><i>Julieta Grasselli<\/i><\/presenter>, <presenter><i>David S. P. Tan<\/i><\/presenter>, <presenter><i>Jennifer E. Friedmann<\/i><\/presenter>, <presenter><i>Jacqueline Vuky<\/i><\/presenter>, <presenter><i>Marina Tschaika<\/i><\/presenter>, <presenter><i>Ruta Slepetis<\/i><\/presenter>, <presenter><i>Georgia D. Kollia<\/i><\/presenter>, <presenter><i>Misena Pacius<\/i><\/presenter>, <presenter><i>Ning Huang<\/i><\/presenter>, <presenter><i>Parul Doshi<\/i><\/presenter>, <presenter><i>Jonathan Baden<\/i><\/presenter>, <presenter><i>Massimo Di Nicola<\/i><\/presenter>. Sf Nectarie Oncology Center and University of Medicine and Pharmacy, Craiova, Romania, Bradford Hill Clinical Research Center, Santiago, Chile, Fundacion Richardet Longo, Instituto Oncologico de Cordoba, Córdoba, Argentina, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania, Institut Paoli-Calmettes, Marseille, France, The Netherlands Cancer Institute, Amsterdam, Netherlands, University Hospitals Leuven, Leuven, Belgium, Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\", Naples, Italy, University of Siena and Center for Immuno-Oncology, Siena, Italy, Maria Sk&#322;odowska Curie National Research Institute of Oncology, Warsaw, Poland, Hospital Italiano De Buenos Aires, Buenos Aires, Argentina, Université Paris-Saclay and Institut Gustave-Roussy, Villejuif, France, Institut Claudius Regaud, Toulouse, France, CEMIC University Hospital, Buenos Aires, Argentina, National University Cancer Institute and Cancer Science Institute, National University of Singapore, Singapore, Singapore, Segal Cancer Center, Jewish General Hospital, Rossy Cancer Network, McGill University, Montreal, QC, Canada, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, Bristol Myers Squibb, Princeton, NJ, Syneos Health, Morrisville, NC, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","CSlideId":"","ControlKey":"f59befd0-a3cd-47ac-b4d9-6d87e2302eed","ControlNumber":"7845","DisclosureBlock":"<B>The Disclosure Block has exceeded its maximum limit. Please call Tech support at (217) 398-1792 for more information.<\/B>","End":"4\/10\/2022 3:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"20160","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT022","PresenterBiography":null,"PresenterDisplayName":"Michael Schenker, MD;PhD","PresenterKey":"5f7039f6-788f-4945-82d7-a1d73b1c1a97","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT022. CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:20:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"9a613c5d-2f87-408d-b4be-f1f76b7c6421","ControlNumber":"9296","DisclosureBlock":"","End":"4\/10\/2022 3:35:00 PM","HasWebcast":null,"Highlights":[],"Id":"20719","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Background: CheckMate 649, a randomized phase 3 study in advanced GC\/GEJC\/EAC, showed superior overall survival (OS) and an acceptable safety profile with 1L NIVO + chemo vs chemo, leading to approval in multiple countries. We present exploratory efficacy analyses by baseline tumor mutational burden (TMB) and gene expression signatures (GES) from CheckMate 649.<br \/>Methods: Whole exome sequencing of baseline tumor tissue and matching blood was performed to derive TMB. TMB-high (H) was defined as &#8805; 199 mutations\/exome (Chang et al. <i>Mol Diagn Ther<\/i> 2019). RNA sequencing of baseline tumor tissue was performed to assess GES. GES included a 4-gene inflammatory (inflam) (Lei et al. <i>Clin Cancer Res<\/i> 2021), a proprietary 12-gene epithelial mesenchymal transition (EMT), 6-gene angiogenesis (angio) (McDermott et al. <i>Nat Med<\/i> 2018), and other stroma- and angiogenesis-related signatures.<br \/>Results: Of 1581 patients (pts) randomized to receive NIVO + chemo or chemo, 685 (43%) were evaluable for TMB (NIVO + chemo 45%, chemo 41%), and 809 (51%) were evaluable for GES (NIVO + chemo 53%, chemo 49%). In pts with PD-ligand (L)1 combined positive score (CPS) &#8805; 5, OS benefit with NIVO + chemo vs chemo was seen in TMB-H pts (HR 0.44), which accounted for 10% of this population, and non-TMB-H pts (HR 0.75) (Table). Similar results were observed when excluding MSI-H pts and will be presented. OS benefit was observed across multiple GES subgroups, although low EMT and angio signature tertiles were associated with greater OS benefit (Table). Similar results were observed with other stroma- and angiogenesis-related GES for all randomized pts and pts with PD-L1 CPS &#60; 5 which will be presented.<br \/>Conclusions: Although the magnitude of benefit was higher in TMB-H and EMT\/angio-low pts, OS benefit with NIVO + chemo vs chemo was observed regardless of TMB, inflam, EMT, and angio GES status.<br \/>Table<table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{3A45BC3C-DC48-425E-8883-390C2E83208E}\"><caption><\/caption><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"4\"><b>PD-L1 CPS &#8805; 5<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b>TMB <\/b><b>(N = 451)<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>GES <\/b><b>(N = 513)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b>Inflam<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>EMT<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>Angio<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>All evaluable <\/b>HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">0.71 (0.58-0.87)<\/td><td rowspan=\"1\" colspan=\"3\">0.72 (0.59-0.87)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>High, n (%)<\/b><\/td><td rowspan=\"1\" colspan=\"1\">43 (10)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">0.44 (0.21-0.93)<\/td><td rowspan=\"1\" colspan=\"1\">0.65 (0.45-0.93)<\/td><td rowspan=\"1\" colspan=\"1\">0.88 (0.64-1.22)<\/td><td rowspan=\"1\" colspan=\"1\">0.86 (0.61-1.20)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Medium, n (%)<\/b><\/td><td rowspan=\"1\" colspan=\"1\">-<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">-<\/td><td rowspan=\"1\" colspan=\"1\">0.65 (0.47-0.91)<\/td><td rowspan=\"1\" colspan=\"1\">0.80 (0.57-1.12)<\/td><td rowspan=\"1\" colspan=\"1\">0.69 (0.50-0.97)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Low, n (%)<\/b><\/td><td rowspan=\"1\" colspan=\"1\">408 (90)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><td rowspan=\"1\" colspan=\"1\">171 (33)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">0.75 (0.61-0.93)<\/td><td rowspan=\"1\" colspan=\"1\">0.77 (0.55-1.07)<\/td><td rowspan=\"1\" colspan=\"1\">0.57 (0.41-0.80)<\/td><td rowspan=\"1\" colspan=\"1\">0.62 (0.44-0.86)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"4\"><b>All randomized<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b>TMB <\/b><b>(N = 685)<\/b><\/td><td rowspan=\"1\" colspan=\"3\"><b>GES <\/b><b>(N = 809)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b>Inflam<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>EMT<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b>Angio<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>All evaluable <\/b>HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">0.79 (0.67-0.93)<\/td><td rowspan=\"1\" colspan=\"3\">0.78 (0.67-0.91)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>High, n (%)<\/b><\/td><td rowspan=\"1\" colspan=\"1\">57 (8)<\/td><td rowspan=\"1\" colspan=\"1\">270 (33)<\/td><td rowspan=\"1\" colspan=\"1\">270 (33)<\/td><td rowspan=\"1\" colspan=\"1\">270 (33)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">0.48 (0.25-0.93)<\/td><td rowspan=\"1\" colspan=\"1\">0.70 (0.53-0.93)<\/td><td rowspan=\"1\" colspan=\"1\">0.88 (0.68-1.15)<\/td><td rowspan=\"1\" colspan=\"1\">0.91 (0.70-1.19)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Medium, n (%)<\/b><\/td><td rowspan=\"1\" colspan=\"1\">-<\/td><td rowspan=\"1\" colspan=\"1\">269 (33)<\/td><td rowspan=\"1\" colspan=\"1\">269 (33)<\/td><td rowspan=\"1\" colspan=\"1\">269 (33)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">-<\/td><td rowspan=\"1\" colspan=\"1\">0.83 (0.64-1.08)<\/td><td rowspan=\"1\" colspan=\"1\">0.84 (0.65-1.10)<\/td><td rowspan=\"1\" colspan=\"1\">0.79 (0.61-1.03)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Low, n (%)<\/b><\/td><td rowspan=\"1\" colspan=\"1\">628 (92)<\/td><td rowspan=\"1\" colspan=\"1\">270 (33)<\/td><td rowspan=\"1\" colspan=\"1\">270 (33)<\/td><td rowspan=\"1\" colspan=\"1\">270 (33)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">HR (95% CI)<\/td><td rowspan=\"1\" colspan=\"1\">0.83 (0.70-0.99)<\/td><td rowspan=\"1\" colspan=\"1\">0.75 (0.58-0.97)<\/td><td rowspan=\"1\" colspan=\"1\">0.68 (0.52-0.88)<\/td><td rowspan=\"1\" colspan=\"1\">0.66 (0.51-0.86)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"5\">HR data are NIVO + chemo vs chemo.<\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Nivolumab,Gastrointestinal cancers: stomach,Immune checkpoint blockade,Chemotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Ming Lei<\/i><\/u><\/presenter>, <presenter><i>Yelena Y. Janjigian<\/i><\/presenter>, <presenter><i>Jaffer A. Ajani<\/i><\/presenter>, <presenter><i>Markus Moehler<\/i><\/presenter>, <presenter><i>Xuya Wang<\/i><\/presenter>, <presenter><i>Lin Shen<\/i><\/presenter>, <presenter><i>Marcelo Garrido<\/i><\/presenter>, <presenter><i>Carlos Gallardo<\/i><\/presenter>, <presenter><i>Kensei Yamaguchi<\/i><\/presenter>, <presenter><i>Lucjan Wyrwicz<\/i><\/presenter>, <presenter><i>Tomasz Skoczylas<\/i><\/presenter>, <presenter><i>Arinilda Bragagnoli<\/i><\/presenter>, <presenter><i>Tianshu Liu<\/i><\/presenter>, <presenter><i>Mustapha Tehfe<\/i><\/presenter>, <presenter><i>Elena Elimova<\/i><\/presenter>, <presenter><i>Mingshun Li<\/i><\/presenter>, <presenter><i>Valerie Poulart<\/i><\/presenter>, <presenter><i>Yu Wang<\/i><\/presenter>, <presenter><i>Parul Doshi<\/i><\/presenter>, <presenter><i>Kohei Shitara<\/i><\/presenter>. Bristol Myers Squibb, Princeton, NJ, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, The University of Texas MD Anderson Cancer Center, Houston, TX, Johannes-Gutenberg University Clinic, Mainz, Germany, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile, Fundacion Arturo Lopez Perez, Santiago, Chile, Cancer Institute Hospital of JFCR, Tokyo, Japan, Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland, II Klinika Chirurgii Ogólnej, Gastroenterologicznej i Nowotworów Uk&#322;adu Pokarmowego, Medical University of Lublin, Lublin, Poland, Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Brazil, Zhongshan Hospital Fudan University, Shanghai, China, Oncology Center – Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada, Princess Margaret Cancer Centre, Toronto, ON, Canada, National Cancer Center Hospital East, Kashiwa, Japan","CSlideId":"","ControlKey":"508ae5a5-253b-471a-8e98-8bd163798059","ControlNumber":"7357","DisclosureBlock":"<B>The Disclosure Block has exceeded its maximum limit. Please call Tech support at (217) 398-1792 for more information.<\/B>","End":"4\/10\/2022 3:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"20161","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT023","PresenterBiography":null,"PresenterDisplayName":"Ming Lei","PresenterKey":"1f714d6a-f7ad-4d94-a43c-96737228f1fd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT023. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): CheckMate 649 biomarker analyses","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:35:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): CheckMate 649 biomarker analyses","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"5254a40f-5db3-4c6e-b3b1-b33afaab7337","ControlNumber":"9297","DisclosureBlock":"","End":"4\/10\/2022 3:50:00 PM","HasWebcast":null,"Highlights":[],"Id":"20720","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Background: In the Phase 3 CASPIAN study, 1L D+EP significantly improved OS vs EP in pts with ES-SCLC with benefit sustained after &#62;3 years of median follow-up (HR 0.71; 95% CI 0.60-0.86; nominal p=0.0003; median OS [mOS] 12.9 mos vs 10.5 mos). 4 SCLC subtypes with distinct therapeutic vulnerabilities were recently identified using 2 different methods (Rudin et al, 2019; Gay et al, 2021) based on differential gene expression. In this exploratory analysis using RNA sequencing (RNAseq) data from CASPIAN, we explored the concordance between the 2 methods and the association of subtypes with OS.<br \/>Methods: Pts with ES-SCLC received 4 cycles of D+EP followed by maintenance D; or up to 6 cycles of EP. RNAseq data were generated from FFPE tumor samples collected at screening. Data cutoff: Mar 22, 2021.<br \/>Results: 57\/268 (21.3%) pts in the D+EP arm and 47\/269 (17.5%) pts in the EP arm had RNAseq data (biomarker-evaluable population; BEP). In the BEP, the % of pts with WHO PS 1 was slightly higher and the % with brain metastases slightly lower at baseline vs the ITT population. In the BEP, mOS was 11.8 mos in the D+EP arm vs 9.1 mos in the EP arm (HR 0.61; 95% CI 0.40-0.92). Prevalence of neuroendocrine (<i>ASCL1 <\/i>and<i> NEUROD1<\/i>) and non-neuroendocrine subtypes (<i>POU2F3 <\/i>and <i>YAP1<\/i> [Rudin] or Inflamed [Gay]) was similar using both methods (Table). However, <i>ASCL1<\/i> was more prevalent and <i>NEUROD1 <\/i>less prevalent with the Rudin method. Inflamed and <i>YAP1<\/i> subtypes (11% and 8% prevalence) showed high concordance between methods. Using either method, the mOS in the D+EP arm was higher in the Inflamed or <i>YAP1<\/i> subtype vs the other 3 subtypes (Table). Analysis of OS by gene signature will be presented.<br \/>Conclusions: Among the 4 subtypes, the Inflamed or <i>YAP1<\/i> subtype showed the longest OS in the D+EP arm, suggesting this may represent a subgroup primed to respond to immunotherapy. Despite the limited sample size, this finding is consistent with other studies.<table class=\"AbstractTable\" id=\"{877587CD-50CB-4E84-884F-0D58166482BB}\"><caption class=\"AbstractTableCaption\"><\/caption><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"4\"><b>mOS (95% CI)<\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Rudin et al, 2019<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><i>ASCL1<\/i><\/td><td rowspan=\"1\" colspan=\"1\"><i>NEUROD1<\/i><\/td><td rowspan=\"1\" colspan=\"1\"><i>POU2F3<\/i><\/td><td rowspan=\"1\" colspan=\"1\"><i>YAP1<\/i>*<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">D+EP<\/td><td rowspan=\"1\" colspan=\"1\">(n=50)<\/td><td rowspan=\"1\" colspan=\"1\">(n=1)<\/td><td rowspan=\"1\" colspan=\"1\">(n=2)<\/td><td rowspan=\"1\" colspan=\"1\">(n=4)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">11.5 (8.4-14.9)<\/td><td rowspan=\"1\" colspan=\"1\">9.5 (NE-NE)<\/td><td rowspan=\"1\" colspan=\"1\">4.8 (2.9-NE)<\/td><td rowspan=\"1\" colspan=\"1\">17.3 (12.8-NE)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">EP<\/td><td rowspan=\"1\" colspan=\"1\">(n=38)<\/td><td rowspan=\"1\" colspan=\"1\">(n=2)<\/td><td rowspan=\"1\" colspan=\"1\">(n=3)<\/td><td rowspan=\"1\" colspan=\"1\">(n=4)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">10.7 (8.1-12.4)<\/td><td rowspan=\"1\" colspan=\"1\">7.1 (4.8-NE)<\/td><td rowspan=\"1\" colspan=\"1\">6.1 (1.3-NE)<\/td><td rowspan=\"1\" colspan=\"1\">6.9 (4.5-NE)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b>Gay et al, 2021<\/b><\/td><td rowspan=\"1\" colspan=\"1\"><i>ASCL1<\/i><\/td><td rowspan=\"1\" colspan=\"1\"><i>NEUROD1<\/i><\/td><td rowspan=\"1\" colspan=\"1\"><i>POU2F3<\/i><\/td><td rowspan=\"1\" colspan=\"1\">Inflamed<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">D+EP<\/td><td rowspan=\"1\" colspan=\"1\">(n=21)<\/td><td rowspan=\"1\" colspan=\"1\">(n=25)<\/td><td rowspan=\"1\" colspan=\"1\">(n=5)<\/td><td rowspan=\"1\" colspan=\"1\">(n=6)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">9.5 (6.1-14.9)<\/td><td rowspan=\"1\" colspan=\"1\">14.6 (8.6-16.6)<\/td><td rowspan=\"1\" colspan=\"1\">6.8 (2.9-NE)<\/td><td rowspan=\"1\" colspan=\"1\">17.6 (11.4-NE)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\">EP<\/td><td rowspan=\"1\" colspan=\"1\">(n=16)<\/td><td rowspan=\"1\" colspan=\"1\">(n=19)<\/td><td rowspan=\"1\" colspan=\"1\">(n=7)<\/td><td rowspan=\"1\" colspan=\"1\">(n=5)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\">8.3 (3.0-15.1)<\/td><td rowspan=\"1\" colspan=\"1\">10.5 (7.9-13.6)<\/td><td rowspan=\"1\" colspan=\"1\">7.5 (1.3-10.2)<\/td><td rowspan=\"1\" colspan=\"1\">11.3 (6.3-NE)<\/td><\/tr><tr><td rowspan=\"1\" colspan=\"5\">*A sample is assigned as <i>YAP1<\/i> subtype per Rudin et al, 2019, when expression of <i>YAP1<\/i> is higher than that of <i>ASCL1<\/i>, <i>NEUROD1<\/i> and <i>POU2F3<\/i>; NE, not estimable<\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Durvalumab,RNA sequencing,CASPIAN,Molecular subtypes,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Mingchao Xie<\/i><\/presenter>, <presenter><i>Priti Chugh<\/i><\/presenter>, <presenter><i>Helen Broadhurst<\/i><\/presenter>, <presenter><i>Zhongwu Lai<\/i><\/presenter>, <presenter><i>David Whitston<\/i><\/presenter>, <presenter><i>Luis Paz-Ares<\/i><\/presenter>, <presenter><i>Carl Gay<\/i><\/presenter>, <presenter><i>Lauren Byers<\/i><\/presenter>, <presenter><i>Charles M. Rudin<\/i><\/presenter>, <presenter><i>Ross Stewart<\/i><\/presenter>, <presenter><i>J. Carl Barrett<\/i><\/presenter>, <presenter><u><i>Yashaswi Shrestha<\/i><\/u><\/presenter>. AstraZeneca, Waltham, MA, Plus-Project Ltd, Alderley Park, United Kingdom, Hospital Universitario 12 de Octubre, Madrid, Spain, The University of Texas MD Anderson Cancer Center, Houston, TX, Memorial Sloan Kettering Cancer Center, New York, NY, AstraZeneca, Cambridge, United Kingdom, AstraZeneca, Gaithersburg, MD","CSlideId":"","ControlKey":"f1e32e5f-52d3-4aad-b1a1-e7dad184a8ef","ControlNumber":"7821","DisclosureBlock":"<b>&nbsp;M. Xie, <\/b> <br><b>AstraZeneca<\/b> Employment, Yes. <br><b>P. Chugh, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>H. Broadhurst, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor, Yes. <br><b>AstraZeneca<\/b> Stock, No. <br><b>Z. Lai, <\/b> <br><b>AstraZeneca<\/b> Employment, Yes. <br><b>AstraZeneca<\/b> Stock, No. <br><b>D. Whitston, <\/b> <br><b>AstraZeneca<\/b> Employment, Yes. <br><b>L. Paz-Ares, <\/b> <br><b>MSD<\/b> Grant\/Contract, Other, Consulting fees, No. <br><b>BMS<\/b> Other, Consulting fees, No. <br><b>AstraZeneca<\/b> Other, Consulting fees, Yes. <br><b>Lilly<\/b> Other, Consulting fees, No. <br><b>Pfizer<\/b> Grant\/Contract, Other, Consulting fees, No. <br><b>Merck<\/b> Other, Consulting fees, No. <br><b>Roche<\/b> Other, Consulting fees, No. <br><b>PharmaMar<\/b> Other, Consulting fees, No. <br><b>Novartis<\/b> Other, Consulting fees, No. <br><b>Servier<\/b> Other, Consulting fees, No. <br><b>Amgen<\/b> Other, Consulting fees, No. <br><b>Sanofi<\/b> Other, Consulting fees, No. <br><b>Bayer<\/b> Other, Consulting fees, No. <br><b>Mirati<\/b> Consulting fees, No. <br><b>GSK<\/b> Other, Consulting fees, No. <br><b>Janssen<\/b> Other, Consulting fees, No. <br><b>Takeda<\/b> Other, Consulting fees, No. <br><b>Genomica<\/b> Other, Board, No. <br><b>Altum sequency<\/b> Other, Board, No. <br><b>C. Gay, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor, Grant\/Contract, Other, Advisory Board\/Consulting\u000d\u000aResearch Support, Yes. <br><b>Bristol Myers Squibb<\/b> Independent Contractor, Other, Advisory Board\/Consulting, No. <br><b>Jazz Pharmaceuticals<\/b> Independent Contractor, Other, Advisory Board\/Consulting, No. <br><b>Kisoji Biotechnology<\/b> Independent Contractor, No. <br><b>L. Byers, <\/b> <br><b>AstraZeneca<\/b> Other, Advisor\/Consultant AND Research Funding, Oncology, No. <br><b>GenMab<\/b> Other, Advisor\/Consultant AND Research Funding, Oncology, No. <br><b>Sierra Oncology<\/b> Other, Advisor\/Consultant AND Research Funding, Oncology, No. <br><b>ToleroPharmaceuticals<\/b> Other, Research Funding, Oncology, No. <br><b>PharmaMar<\/b> Other, Advisor\/Consultant only, No. <br><b>AbbVie<\/b> Other, Advisor\/Consultant only, No. <br><b>Bristol-Myers Squibb<\/b> Other, Advisor\/Consultant only, No. <br><b>Alethia<\/b> Other, Advisor\/Consultant only, No. <br><b>Merck<\/b> Other, Advisor\/Consultant only, No. <br><b>Pfizer<\/b> Other, Advisor\/Consultant only, No. <br><b>Jazz Pharmaceuticals<\/b> Other, Advisor\/Consultant only, No. <br><b>Genentech<\/b> Other, Advisor\/Consultant only, No. <br><b>Debiopharm Group<\/b> Other, Advisor\/Consultant only, No. <br><b>C. M. Rudin, <\/b> <br><b>AbbVie<\/b> Independent Contractor, No. <br><b>Amgen<\/b> Independent Contractor, No. <br><b>AstraZeneca<\/b> Independent Contractor, No. <br><b>Epizyme<\/b> Independent Contractor, No. <br><b>Genentech\/Roche<\/b> Independent Contractor, No. <br><b>Ipsen<\/b> Independent Contractor, No. <br><b>Jazz<\/b> Independent Contractor, No. <br><b>Lilly<\/b> Independent Contractor, No. <br><b>Syros<\/b> Independent Contractor, No. <br><b>Bridge Medicines<\/b> Independent Contractor, No. <br><b>Harpoon Therapeutics<\/b> Independent Contractor, No. <br><b>Earli<\/b> Stock Option, No. <br><b>R. Stewart, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock Option, Yes. <br><b>Pfizer<\/b> Stock, No. <br><b>J. Barrett, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>Y. Shrestha, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock, Yes.","End":"4\/10\/2022 4:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"20162","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT024","PresenterBiography":null,"PresenterDisplayName":"Yashaswi Shrestha","PresenterKey":"7c734fcf-3a09-445c-9a77-a4e8a2d84a60","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT024. Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 3:50:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"110fe237-c128-4d0d-92ce-ffcb9ef72284","ControlNumber":"9299","DisclosureBlock":"","End":"4\/10\/2022 4:05:00 PM","HasWebcast":null,"Highlights":[],"Id":"20722","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"11","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"BT8009 is a Bicycle&#174; Toxin Conjugate (BTC&#8482;), a novel class of chemically synthesized molecules, comprising a bicyclic peptide targeting Nectin-4 tumor antigen, linked to cytotoxin (monomethyl auristatin E [MMAE]) via a valine-citrulline (val-cit) cleavable linker. Due to their small size, BTCs represent a unique therapeutic class, combining the pharmacology normally associated with a biologic with the pharmacokinetic properties of a small molecule. Here, we describe the preliminary monotherapy dose escalation results of the ongoing multicenter Phase I\/II clinical trial (NCT04561362) that assesses the safety and tolerability of BT8009 administration in patients with advanced solid tumors associated with Nectin-4 expression, not exposed to enfortumab vedotin. Patients were treated until disease progression or intolerable toxicity, with tumor assessments for response per RECIST taken every two months. Nectin-4 expression levels were measured in tumor tissue. Thirty-four patients were initiated on weekly BT8009 (7 patients at 2.5 mg\/m<sup>2<\/sup>, 20 patients at 5.0 mg\/m<sup>2<\/sup>, and 4 patients at 7.5 mg\/m<sup>2<\/sup>) or biweekly BT8009 (3 patient at 7.5 mg\/m<sup>2<\/sup>). Baseline demographics were 62% patients were male, 44% and 56% were ECOG 0 and ECOG 1, respectively, median age was 65.5 years. BT8009 exhibits linear pharmacokinetics. The most common treatment-related adverse events were nausea (14 patients, 41%; &#8805; G3 1 patient, 3%), fatigue (13 patients, 38%; &#8805; G3 2 patients, 6%), anorexia (11 patients, 32%; &#8805; G3 0 patients), constipation (10 patients, 29%; &#8805; G3 1 patient, 3%) and anemia (10 patients, 29%; &#8805; G3 3 patients, 9%). To date, BT8009 had low incidences of ocular disorders (3%), hyperglycemia (6%), neuropathy (6%), and rash (18%). There was 1 dose-limiting toxicity (G3 asthenia) reported at the 7.5 mg\/m<sup>2<\/sup> weekly dose level. Six patients (18%) experienced an SAE, with only 1 related SAE (vomiting). Treatment-emergent AEs resulting in treatment discontinuation, dose interruption, or reductions were observed in 2 patients (6%), 11 patients (32%), and 5 patients (15%), respectively. Preliminary confirmed responses observed in patients with urothelial carcinoma (UC) enrolled in the 5 mg\/m<sup>2 <\/sup>cohort show 4\/8 patients with a complete response (CR) or partial response (PR), including 1\/8 patients with a CR and 3\/8 patients with a PR, and 2\/8 patients (25%) with stable disease (SD), reflecting a 50% overall response rate and a 75% disease control rate in UC patients for this cohort. BT8009 exhibits a promising preliminary tolerability profile and preliminary antitumor activity. The molecule will continue to be explored in the current dose-escalation\/dose-expansion study of BT8009 monotherapy and in combination with nivolumab.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Phase I,Nectin-4,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Meredith McKean<\/i><\/u><\/presenter>, <presenter><i>Capucine Baldini<\/i><\/presenter>, <presenter><i>Loic Verlingue<\/i><\/presenter>, <presenter><i>Bernard Doger<\/i><\/presenter>, <presenter><i>Gerald Falchook<\/i><\/presenter>, <presenter><i>Antoine Italiano<\/i><\/presenter>, <presenter><i>Julia Lostes<\/i><\/presenter>, <presenter><i>Oscar Reig<\/i><\/presenter>, <presenter><i>Roshawn Watson<\/i><\/presenter>, <presenter><i>Sebastien Hazard<\/i><\/presenter>, <presenter><i>Dominic Smethurst<\/i><\/presenter>, <presenter><i>Giulia Fulci<\/i><\/presenter>, <presenter><i>Hongmei Xu<\/i><\/presenter>, <presenter><i>Phil Jeffery<\/i><\/presenter>, <presenter><i>Kevin Lee<\/i><\/presenter>, <presenter><i>Irene Braña<\/i><\/presenter>, <presenter><i>Sophie Cousin<\/i><\/presenter>, <presenter><i>Elisa Fontana<\/i><\/presenter>, <presenter><i>Hendrik-Tobias Arkenau<\/i><\/presenter>. Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN, Institut Gustave Roussy, Villejuif, France, START Madrid FJD, Madrid, Spain, Sarah Cannon Research Institute at HealthONE, Denver, CO, Institute Bergonié, Bordeaux, France, Vall d’ Hebron Institute of Oncology, Barcelona, Spain, Hospital Clinic Barcelona, Barcelona, Spain, Bicycle Therapeutics, Lexington, MA, Bicycle Therapeutics, Cambridge, United Kingdom, Sarah Cannon Research Institute UK, London, United Kingdom","CSlideId":"","ControlKey":"2e0bb818-9d6e-404c-a09b-b07c3a3aecc0","ControlNumber":"7971","DisclosureBlock":"<b>&nbsp;M. McKean, <\/b> <br><b>Array BioPharma<\/b> Other, Institutional consultant\/advisory role, No. <br><b>AstraZeneca<\/b> Other, Institutional consultant\/advisory role, No. <br><b>Pfizer<\/b> Other, Institutional consultant\/advisory role, No. <br><b>Regeneron<\/b> Other, Institutional consultant\/advisory role, No. <br><b>Ascentage Pharma Group<\/b> Other, Institutional research funding, No. <br><b>Bicycle Therapeutics<\/b> Institutional research funding, Yes. <br><b>Dragonfly Therapeutics<\/b> Other, Institutional research funding, No. <br><b>Epizyme<\/b> Other, Institutional research funding, No. <br><b>Excelixis<\/b> Other, Institutional research funding, No. <br><b>Genentech<\/b> Other, Institutional research funding, No. <br><b>GlaxoSmithKline<\/b> Other, Institutional research funding, No. <br><b>IDEAYA<\/b> Other, Institutional research funding, No. <br><b>Ikena Oncology<\/b> Other, Institutional research funding, No. <br><b>Infinity Pharmaceuticals<\/b> Other, Institutional research funding, No. <br><b>Jacobio<\/b> Other, Institutional research funding, No. <br><b>Moderna Therapeutics<\/b> Other, Institutional research funding, No. <br><b>NBE Therapeutics<\/b> Other, Institutional research funding, No. <br><b>Novatis<\/b> Other, Institutional research funding, No. <br><b>Oncorus<\/b> Other, Institutional research funding. <br><b>Plexxikon<\/b> Other, Institutional research funding, No. <br><b>C. Baldini, <\/b> <br><b>Astra Zeneca<\/b> Other, Advisory role, No. <br><b>BMS<\/b> Other, Advisory role, No. <br><b>Sanofi<\/b> Other, Advisory role, No. <br><b>L. Verlingue, <\/b> <br><b>Adaptherapy<\/b> Other, Personal fees, No. <br><b>SurgiQual Institute<\/b> Other, Personal fees, No. <br><b>Resolved<\/b> Other, Personal fees, No. <br><b>Klineo<\/b> Other, Personal fees, No. <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract, No. <br><b>Servier<\/b> Other, Non-personal fees, No. <br><b>Pierre-Fabre<\/b> Other, Non-personal fees. <br><b>Astrazeneca<\/b> Other, Research grant, No. <br><b>BMS<\/b> Other, Research grant, No. <br><b>Boehringer Ingelheim<\/b> Other, Research grant, No. <br><b>Janssen Cilag<\/b> Other, Research grant, No. <br><b>Merck<\/b> Other, Research grant, No. <br><b>Novartis<\/b> Other, Research grant, No. <br><b>Onxeo<\/b> Other, Research grant, No. <br><b>Pfizer<\/b> Other, Research grant, No. <br><b>Roche<\/b> Other, Research grant, No. <br><b>Sanofi<\/b> Other, Research grant, No.<br><b>B. Doger, <\/b> None.&nbsp;<br><b>G. Falchook, <\/b> <br><b>Wolters Kluwer<\/b> Other, Royalties, No. <br><b>Silicon<\/b> Other, Advisory role, No. <br><b>Navire<\/b> Other, Advisory role, No. <br><b>Turning Point<\/b> Other, Advisory role, No. <br><b>Predicine<\/b> Other, Advisory role, No. <br><b>Inspirna<\/b> Other, Advisory role, No. <br><b>Regeneron<\/b> Other, Advisory role, No. <br><b>Total Health Conferencing<\/b> Other, Speaker honorarium, No. <br><b>Rocky Mountain Oncology Society<\/b> Other, Speaker honorarium, No. <br><b>Sarah Cannon Research Institute<\/b> Travel, No. <br><b>A. Italiano, <\/b> <br><b>Bayer<\/b> Grant\/Contract, Other, Personal Fees, No. <br><b>MSD<\/b> Grant\/Contract, No. <br><b>Merck<\/b> Grant\/Contract, Other, Non-financial support, No. <br><b>Astra Zeneca<\/b> Grant\/Contract, No. <br><b>BMS<\/b> Grant\/Contract, No. <br><b>Pharmamar<\/b> Grant\/Contract, No. <br><b>Roche<\/b> Grant\/Contract, No. <br><b>Seven and Eight<\/b> Grant\/Contract, No.<br><b>J. Lostes, <\/b> None.&nbsp;<br><b>O. Reig, <\/b> <br><b>BMS<\/b> Other, Personal Fees, No. <br><b>Ipsen<\/b> Other, Personal Fees, No. <br><b>EISAI<\/b> Other, Personal Fees, No. <br><b>EUSA Pharma<\/b> Other, Personal Fees, No. <br><b>Pfizer<\/b> Other, Personal Fees, No. <br><b>R. Watson, <\/b> <br><b>Bicycle Theraputics<\/b> Employment, Stock Option. <br><b>S. Hazard, <\/b> <br><b>Bicycle Theraputics<\/b> Employment, Stock Option. <br><b>D. Smethurst, <\/b> <br><b>Bicycle Therapeutics<\/b> Employment, Stock Option. <br><b>G. Fulci, <\/b> <br><b>Bicycle Therapeutics<\/b> Employment, Stock Option. <br><b>H. Xu, <\/b> <br><b>Bicycle Therapeutics<\/b> Employment, Stock Option. <br><b>P. Jeffery, <\/b> <br><b>Bicycle Therapeutics<\/b> Employment, Stock Option. <br><b>K. Lee, <\/b> <br><b>Bicycle Therapeutics<\/b> Employment, Stock Option. <br><b>I. Braña, <\/b> <br><b>Achilles Therapeutics<\/b> Institutional consultant\/advisory role. <br><b>Cancer Expert Now<\/b> Institutional consultant\/advisory role. <br><b>eTheRNA Immunotherapies<\/b> Institutional consultant\/advisory role. <br><b>Merck Sharp & Dohme<\/b> Institutional consultant\/advisory role. <br><b>Rakuten Medical<\/b> Institutional consultant\/advisory role. <br><b>Sanofi<\/b> Institutional consultant\/advisory role. <br><b>Bristol-Myers Squibb<\/b> Speakers' Bureau. <br><b>Merck Serono<\/b> Speakers' Bureau. <br><b>Roche<\/b> Speakers' Bureau. <br><b>AstraZeneca;<\/b> Institutional Research Funding. <br><b>Bristol-Myers Squibb<\/b> Institutional Research Funding. <br><b>Celgene<\/b> Institutional Research Funding. <br><b>GlaxoSmithKline<\/b> Institutional Research Funding. <br><b>Gliknik<\/b> Institutional Research Funding. <br><b>Janssen Oncology<\/b> Institutional Research Funding. <br><b>Kura Oncology<\/b> Institutional Research Funding. <br><b>Merck Sharp & Dohme<\/b> Institutional Research Funding. <br><b>Nanobiotix<\/b> Institutional Research Funding. <br><b>Novartis<\/b> Institutional Research Funding. <br><b>Orion Pharma GmbH<\/b> Institutional Research Funding.<br><b>H. Arkenau, <\/b> None.","End":"4\/10\/2022 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"20163","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"12","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT025","PresenterBiography":null,"PresenterDisplayName":"Laura DeBusk","PresenterKey":"1b1e6a9d-8986-4958-bc1e-df414fca39e6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT025. BT8009-100 phase I\/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:05:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"BT8009-100 phase I\/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"b575e9e5-3734-43e1-b2e2-c6bcf3a63a46","ControlNumber":"9301","DisclosureBlock":"","End":"4\/10\/2022 4:20:00 PM","HasWebcast":null,"Highlights":[],"Id":"20724","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"13","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Introduction: The ALTERNATE trial randomized postmenopausal women with ER Allred 6-8 HER2- breast cancer to 6 months of NET with anastrozole (A), fulvestrant (F) or the combination (A+F). Biopsies were taken preNET and after 4-weeks(wks). Patients with Ki67 values &#62;10% at 4-wks were offered triage to neoadjuvant chemotherapy. Patients with on-treatment Ki67 &#8804; 10% who completed NET underwent surgery and Ki67 was reassessed. The primary endpoint was endocrine-sensitive disease rate (ESDR). ESD is defined as pCR or PEPI-0 residual disease (pT1-2, pN0, Ki67 &#8804; 2.7%). We previously reported that the ESDR difference between the F-containing arms and the A arm was not &#62;10% (ASCO 2020) and that baseline RNA-seq-based intrinsic subtypes predicted outcomes overall (SABCS 2021). Herein we describe relationships between PAM50 intrinsic subtype and Ki67 values by treatment arm because comparative drug effectiveness in adjuvant endocrine therapy studies in ER+ HER2- breast cancer can be predicted by the degree of Ki67 suppression (PMC3518447).<br \/>Methods: 743 of the 1297 eligible patients (A: 264; F: 231; A+F: 248) had RNA extracted from preNET frozen tumor biopsies with &#62;50% tumor content and subjected to RNA seq. Intrinsic subtypes were then assigned as LumA, LumB, and NonLum (Basal or HER2-E) using open-source PAM50-based informatics. Differences in the proportion with wk4 Ki67 &#62; 10%, % change in wk4 ki67, and surgical CCCA (Ki67 &#8804; 2.7%) rate (sxCCCA) between treatments and by intrinsic subtype was assessed using stratified logistic regression, Wilcoxon rank sum test, and Fisher&#8217;s exact test, respectively. Analysis of sxCCCA excluded those who failed to complete NET for reasons other than disease progression or early Ki67 &#62;10%.<br \/>Results: Amongst the 358 LumA cases there were no significant differences in Ki67-based endpoints between treatments. Among the 292 LumB cases, the wk4 ki67 &#62; 10% rate was lower with A+F (19.4%) than A (43%) (P=0.0002) and was somewhat lower in F (31%) versus A (P=0.076). The % change in wk4 Ki67 in LumB cases, adjusted for baseline Ki67, showed markedly superior suppression for A+F versus A (-90% vs. -77%; P=&#60;0.0001) and versus F (-90% vs. -80%; P=0.0026). Furthermore sxCCCA rates were significantly higher with A+F than A (53% vs. 25% P = &#60;0.0001) and somewhat higher for F (37%) than A (p=0.068), indicating that superior antiproliferative effects for A+F persist after 6 months on therapy. Lack of Ki67 suppression in response to treatment was observed in the majority of 43 NonLum samples regardless of treatment.<br \/>Conclusion: The combination of A+F was significantly more effective than either drug alone for the control of LumB breast cancer cell proliferation. This suggests that A+F may be a more effective adjuvant endocrine therapy than A alone in LumB disease. The lower Ki67 suppression with A alone also suggests that poorer outcome in some LumB tumors may be due to insufficient ER targeting rather than ER-independent tumor growth<br \/>Support: U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG), NCI BIQSFP, BCRF, Genentech, AstraZeneca. https:\/\/acknowledgments.alliancefound.org. (MJE) CPRIT RR140033, P50-CA186784, P50-CA58223, U01-CA214125, U24-CA210954, Gift from Ralph and Lisa Eads, McNair Scholarship.<br \/>ClinicalTrials.gov Identifier: NCT01953588","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Breast cancer,Neoadjuvant Endocrine Therapy,Intrinsic Subtype,Ki67,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><i>Matthew J. Ellis<\/i><\/presenter>, <presenter><u><i>Meenakshi Anurag<\/i><\/u><\/presenter>, <presenter><i>Jeremy Hoog<\/i><\/presenter>, <presenter><i>Aranzazu Fernandez-Martinez<\/i><\/presenter>, <presenter><i>Cheng Fan<\/i><\/presenter>, <presenter><i>Richard Gibbs<\/i><\/presenter>, <presenter><i>Souzan Sanati<\/i><\/presenter>, <presenter><i>Kiran Vij<\/i><\/presenter>, <presenter><i>Mark Watson<\/i><\/presenter>, <presenter><i>Travis Dockter<\/i><\/presenter>, <presenter><i>Olwen Hahn<\/i><\/presenter>, <presenter><i>Joseph Guenther<\/i><\/presenter>, <presenter><i>Abigail Caudle<\/i><\/presenter>, <presenter><i>Erica Crouch<\/i><\/presenter>, <presenter><i>Amy Tiersten<\/i><\/presenter>, <presenter><i>Monica Mita<\/i><\/presenter>, <presenter><i>Wajeeha Razaq<\/i><\/presenter>, <presenter><i>Tina J. Hieken<\/i><\/presenter>, <presenter><i>Yang Wang<\/i><\/presenter>, <presenter><i>A. Marilyn Leitch<\/i><\/presenter>, <presenter><i>Gary W. Unzeitig<\/i><\/presenter>, <presenter><i>Eric Winer<\/i><\/presenter>, <presenter><i>Anna Weiss<\/i><\/presenter>, <presenter><i>Kelly Hunt<\/i><\/presenter>, <presenter><i>Ann H. Partridge<\/i><\/presenter>, <presenter><i>Charles M. Perou<\/i><\/presenter>, <presenter><i>Vera Suman<\/i><\/presenter>, <presenter><i>Cynthia X. Ma<\/i><\/presenter>, <presenter><i>Lisa A. Carey<\/i><\/presenter>. Baylor College of Medicine, Houston, TX, Washington University School of Medicine, St. Louis, MO, University of North Carolina, Chapel Hill, NC, Cedars-Sinai Medical Center, Los Angeles, CA, Alliance Statistics and Data Center and Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL, Saint Elizabeth Medical Center South, Edgewood, KY, MD Anderson Cancer Center, Houston, TX, Mount Sinai Hospital, New York, NY, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Mayo Clinic, Rochester, MN, Presbyterian Kaseman Hospital, Albuquerque, NM, University of Texas Southwestern Medical Center, Dallas, TX, Doctor's Hospital of Laredo, Laredo, TX, Dana-Farber Cancer Institute, Boston, MA","CSlideId":"","ControlKey":"2d22a820-45d9-4fa8-91e1-d12180eadffb","ControlNumber":"7727","DisclosureBlock":"<b>&nbsp;M. J. Ellis, <\/b> <br><b>Veracyte<\/b> Patent, Yes. <br><b>AstraZenica<\/b> Independent Contractor, Yes. <br><b>Novartis<\/b> Independent Contractor. <br><b>Abbvie<\/b> Independent Contractor, No. <br><b>Lilly<\/b> Independent Contractor, Yes. <br><b>Sermonix<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor.<br><b>M. Anurag, <\/b> None..<br><b>J. Hoog, <\/b> None..<br><b>A. Fernandez-Martinez, <\/b> None..<br><b>C. Fan, <\/b> None..<br><b>R. Gibbs, <\/b> None..<br><b>S. Sanati, <\/b> None..<br><b>K. Vij, <\/b> None..<br><b>M. Watson, <\/b> None..<br><b>T. Dockter, <\/b> None..<br><b>O. Hahn, <\/b> None..<br><b>J. Guenther, <\/b> None..<br><b>A. Caudle, <\/b> None..<br><b>E. Crouch, <\/b> None..<br><b>A. Tiersten, <\/b> None..<br><b>M. Mita, <\/b> None..<br><b>W. Razaq, <\/b> None.&nbsp;<br><b>T. J. Hieken, <\/b> <br><b>Genentech<\/b> Grant\/Contract, No. <br><b>SkyliveDX BV<\/b> Grant\/Contract.<br><b>Y. Wang, <\/b> None.&nbsp;<br><b>A. M. Leitch, <\/b> <br><b>AstraZenica<\/b> Independent Contractor, No.<br><b>G. W. Unzeitig, <\/b> None..<br><b>E. Winer, <\/b> None..<br><b>A. Weiss, <\/b> None..<br><b>K. Hunt, <\/b> None..<br><b>A. H. Partridge, <\/b> None.&nbsp;<br><b>C. M. Perou, <\/b> <br><b>Veracyte<\/b> Patent, Yes.<br><b>V. Suman, <\/b> None.&nbsp;<br><b>C. X. Ma, <\/b> <br><b>AstraZenica<\/b> Independent Contractor, Yes. <br><b>Sanofi-Genzyme<\/b> Independent Contractor, Yes. <br><b>Pfizer<\/b> Grant\/Contract.<br><b>L. A. Carey, <\/b> None.","End":"4\/10\/2022 4:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"20164","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"14","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT026","PresenterBiography":"","PresenterDisplayName":"Meenakshi Anurag, PhD","PresenterKey":"a767631c-4072-463b-bfdf-205a62a42f69","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT026. The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial.","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:20:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial.","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"0e7a4f97-f9cd-400d-9d4e-9b77d352b782","ControlNumber":"9302","DisclosureBlock":"","End":"4\/10\/2022 4:35:00 PM","HasWebcast":null,"Highlights":[],"Id":"20725","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"15","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Background: INO-VATE (NCT01564784) demonstrated higher rates of remission, MRD-negativity, and improved overall survival (hazard ratio 0.75, one-sided <i>P<\/i>=0.01) for pts with R\/R ALL who received InO vs standard chemotherapy (SC). Here we explore the potential association between leukemic molecular profiles and efficacy of InO.<br \/>Methods: Pts with CD22+ ALL due to receive salvage treatment were randomized to InO or SC; clinical methods and results were published previously (Kantarjian HM, et al. N Engl J Med 2016; PMID: 27292104). Bone marrow samples collected at screening post protocol amendment 2 underwent RNA-sequencing with analysis of gene expression profile, fusions, and genomic alterations. Data cutoff: Jan 4, 2017.<br \/>Results: Of 326 pts in the INO-VATE intent-to-treat (ITT) population, 91 (InO, 43; SC, 48) had samples evaluable for molecular profiling. Baseline characteristics were similar in the evaluable pts vs the ITT population. Most common (&#8805;5%) ALL subtypes were <i>BCR-ABL1<\/i>-positive (14%), low hypodiploidy (12%), Philadelphia chromosome (Ph)-like (11%), <i>KMT2A-<\/i>rearranged (9%), and <i>DUX4-<\/i>rearranged (6%); 29% (26\/91) of pts could not be subtyped due to low blast counts. Most common (&#8805;5%) non-<i>BCR-ABL1<\/i> oncogenic fusions detected were <i>IGH-CRLF2<\/i> (8%), and <i>KMT2A-AFF1<\/i> (6%). Among non-fusion genomic alterations, those involving chromatin modifying genes featured prominently (e.g. <i>KMT2D<\/i>, 18%; <i>CREBBP<\/i>, 12%; <i>KMT2C<\/i>, 11%; <i>ARID2<\/i>, 9%; <i>ARID1A<\/i>, 8%; <i>SET2D<\/i>, 7%; <i>EP300<\/i>, 6%). Other commonly altered (&#8805;9%) genes included <i>TP53<\/i> (14%), <i>NOTCH1<\/i> (11%), <i>KRAS<\/i> (9%), and <i>PAX5<\/i> (9%).<br \/>Similar to the overall findings of INO-VATE, complete remission (CR)\/CR with incomplete count recovery (CRi) rates were numerically higher with InO vs SC across ALL subtypes, including but not limited to, low hypodiploidy (67% [2\/3] vs 13% [1\/8], <i>P<\/i>=0.15), Ph-like (83% [5\/6] vs 0% [0\/4], <i>P<\/i>=0.02), and <i>KMT2A<\/i> (100% [2\/2] vs 17% [1\/6], <i>P<\/i>=0.11), although not in <i>BCR-ABL1<\/i>-positive (67% [4\/6] vs 57% [4\/7], <i>P<\/i>=0.59). Within pts bearing common non-<i>BCR-ABL1 <\/i>oncogenic fusions, CR\/CRi was seen for InO including for <i>IGH-CRLF2<\/i> (50% [1\/2] vs 20% [1\/5] for SC), <i>KMT2A-AFF1<\/i> (100% [1\/1] vs 25% [1\/4] for SC), and <i>IGH-DUX4<\/i> (100% [3\/3] vs 0% [0\/1] for SC). Consistent with a previous report (Yang X, et al. Blood 2019; 134 [Suppl 1]: 3888) CR\/CRi rates were high for InO in pts with <i>TP53<\/i> alterations (100% [5\/5] vs 13% [1\/8] for SC, <i>P<\/i>=0.0047).<br \/>Conclusions: This retrospective, exploratory analysis of INO-VATE demonstrated potential for benefit with InO for ALL pts across leukemic subtypes, including Ph-like, and for those bearing diverse fusions. Further exploration of Ph-like subtype or <i>TP53<\/i> alterations as candidate predictive biomarkers for InO in pts with R\/R ALL is warranted.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Inotuzumab ozogamicin,CD22,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Yaqi Zhao<\/i><\/u><\/presenter>, <presenter><i>A Douglas Laird<\/i><\/presenter>, <presenter><i>Kathryn Roberts<\/i><\/presenter>, <presenter><i>Rolla Yafawi<\/i><\/presenter>, <presenter><i>Hagop Kantarjian<\/i><\/presenter>, <presenter><i>Daniel J. DeAngelo<\/i><\/presenter>, <presenter><i>Matthias Stelljes<\/i><\/presenter>, <presenter><i>Michaela Liedtke<\/i><\/presenter>, <presenter><i>Wendy Stock<\/i><\/presenter>, <presenter><i>Nicola Gökbuget<\/i><\/presenter>, <presenter><i>Susan O'Brien<\/i><\/presenter>, <presenter><i>Elias Jabbour<\/i><\/presenter>, <presenter><i>Ryan D. Cassaday<\/i><\/presenter>, <presenter><i>Melanie R. Loyd<\/i><\/presenter>, <presenter><i>Scott Olsen<\/i><\/presenter>, <presenter><i>Geoffrey Neale<\/i><\/presenter>, <presenter><i>Xueli Liu<\/i><\/presenter>, <presenter><i>Erik Vandendries<\/i><\/presenter>, <presenter><i>Charles G. Mullighan<\/i><\/presenter>, <presenter><i>Anjali Advani<\/i><\/presenter>. St. Jude Children’s Research Hospital, Memphis, TN, Pfizer Inc, La Jolla, CA, University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, Universitätsklinikum Münster, Munster, Germany, Stanford Cancer Institute, Stanford, CA, University of Chicago, Chicago, IL, Goethe University, Frankfurt, Germany, University of California, Irvine Medical Center, Orange County, CA, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, Pfizer Inc, Groton, CT, Pfizer Inc, Cambridge, MA, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","CSlideId":"","ControlKey":"501a431d-0030-44a9-9dff-809d583a23b0","ControlNumber":"8022","DisclosureBlock":"&nbsp;<b>Y. Zhao, <\/b> None.&nbsp;<br><b>A. D. Laird, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock.<br><b>K. Roberts, <\/b> None.&nbsp;<br><b>R. Yafawi, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock, Yes. <br><b>H. Kantarjian, <\/b> <br><b>AbbVie<\/b> Grant\/Contract, Other, Honoraria. <br><b>Amgen<\/b> Grant\/Contract, Other, Honoraria. <br><b>Daiichi-Sankyo<\/b> Grant\/Contract, Other, Honoraria. <br><b>Pfizer<\/b> Grant\/Contract, Other, Honoraria. <br><b>Ascentage<\/b> Grant\/Contract. <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract. <br><b>Immunogen<\/b> Grant\/Contract. <br><b>Jazz Pharmaceuticals<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Grant\/Contract. <br><b>Bio Ascend<\/b> Honoraria. <br><b>Novartis<\/b> Other, Honoraria. <br><b>Takeda<\/b> Other, Honoraria. <br><b>Adaptive Biotechnologies<\/b> Honoraria. <br><b>Aptitude Health<\/b> Other, Honoraria. <br><b>Delta Fly<\/b> Honoraria. <br><b>Janssen Global<\/b> Other, Honoraria. <br><b>Oxfrod Biomedical<\/b> Other, Honoraria. <br><b>Actinium<\/b> Advisory board. <br><b>D. J. DeAngelo, <\/b> <br><b>Amgen<\/b> Other, honoraria. <br><b>Autolos<\/b> Other, honoraria. <br><b>Agios<\/b> Other, honoraria. <br><b>Blueprint Pharmaceuticals<\/b> Grant\/Contract, Other, honoraria. <br><b>Forty-Seven<\/b> Other, honoraria. <br><b>Incyte<\/b> Other, honoraria. <br><b>Jazz Pharmaceuticals<\/b> Other, honoraria. <br><b>Kite Pharma<\/b> Other, honoraria. <br><b>Novartis<\/b> Grant\/Contract, Other, honoraria. <br><b>Pfizer<\/b> Other, honoraria. <br><b>Shire<\/b> Other, honoraria. <br><b>Takdea<\/b> Other, honoraria. <br><b>Abbvie<\/b> Grant\/Contract. <br><b>Glycomimetics<\/b> Grant\/Contract. <br><b>M. Stelljes, <\/b> <br><b>Pfizer Inc<\/b> Grant\/Contract, Other, Honoraria. <br><b>M. Liedtke, <\/b> <br><b>Pfizer<\/b> Grant\/Contract, Other, Honoraria. <br><b>Amgen<\/b> Grant\/Contract, Honoraria. <br><b>W. Stock, <\/b> <br><b>ADC Therapeutics<\/b> Grant\/Contract, Honoraria. <br><b>Agios<\/b> Grant\/Contract, Other, Honoraria. <br><b>Amgen<\/b> Grant\/Contract, Honoraria. <br><b>Astellas<\/b> Grant\/Contract, Other, Honoraria. <br><b>Gilead<\/b> Grant\/Contract, Honoraria. <br><b>Jazz<\/b> Grant\/Contract, Gilead. <br><b>Jazz Pharmaceuticals<\/b> Grant\/Contract, honoraria. <br><b>Kite Pharma<\/b> Grant\/Contract, Other, honoraria. <br><b>Pfizer<\/b> Grant\/Contract, honoraria. <br><b>Sigma-Tau<\/b> Grant\/Contract, Other, honoraria. <br><b>N. Gökbuget, <\/b> <br><b>Pfizer<\/b> Grant\/Contract, Honoraria. <br><b>Amgen<\/b> Grant\/Contract, Honoraria. <br><b>S. O'Brien, <\/b> <br><b>Pfizer Inc<\/b> Grant\/Contract, Honoraria. <br><b>E. Jabbour, <\/b> <br><b>Amgen<\/b> Grant\/Contract, consultancy. <br><b>Pfizer<\/b> Grant\/Contract, consultancy. <br><b>Takeda<\/b> Grant\/Contract, consultancy. <br><b>Adaptive Biotechnologies<\/b> Grant\/Contract, consultancy. <br><b>AbbVie<\/b> Grant\/Contract, consultancy. <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract, consultancy. <br><b>Spectrum<\/b> Grant\/Contract, consultancy. <br><b>Genetech<\/b> Grant\/Contract, consultancy. <br><b>R. D. Cassaday, <\/b> <br><b>Amgen<\/b> Grant\/Contract, consultancy. <br><b>Kite\/Gilead<\/b> Grant\/Contract, consultancy and honoraria. <br><b>Pfizer<\/b> Grant\/Contract, consultancy. <br><b>PeproMene Bio<\/b> Data Safety and Monitoring board. <br><b>Sevier<\/b> Grant\/Contract. <br><b>Vanda Pharmaceuticals<\/b> Grant\/Contract. <br><b>Seagen<\/b> Spouse employed by and owns stocks.<br><b>M. R. Loyd, <\/b> None..<br><b>S. Olsen, <\/b> None.&nbsp;<br><b>G. Neale, <\/b> <br><b>National Cancer Institute (P30 CA021765)<\/b> Grant\/Contract. <br><b>X. Liu, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock. <br><b>E. Vandendries, <\/b> <br><b>Pfizer Inc<\/b> Employment, Stock. <br><b>C. G. Mullighan, <\/b> <br><b>Pfizer<\/b> Grant\/Contract. <br><b>AbbVie<\/b> Grant\/Contract. <br><b>Amgen<\/b> Stock, Honoraria. <br><b>Illumina<\/b> Honoraria. <br><b>A. Advani, <\/b> <br><b>Jazz Pharmaceutical<\/b> consultancy. <br><b>Beam Therapeutics<\/b> consultancy. <br><b>Glycomimetrics<\/b> Grant\/Contract, consultancy. <br><b>Seattle Genetics<\/b> Grant\/Contract. <br><b>Immunogen<\/b> Grant\/Contract. <br><b>AbbVie<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Kite<\/b> Grant\/Contract. <br><b>MacroGenics<\/b> Grant\/Contract.","End":"4\/10\/2022 4:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"20165","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"16","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT027","PresenterBiography":null,"PresenterDisplayName":"Gemma Shay","PresenterKey":"0a4e817c-caae-4900-a0af-77ea60a552cf","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT027. Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed\/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:35:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed\/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"3a4b8a49-b0bd-4630-af7b-589889231f63","ControlNumber":"9303","DisclosureBlock":"","End":"4\/10\/2022 4:50:00 PM","HasWebcast":null,"Highlights":[],"Id":"20726","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"17","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Benedito A. Carneiro<\/i><\/u><\/presenter>. Brown University, Lifespan, Providence, RI","CSlideId":"","ControlKey":"4bb097b8-5b52-4eaa-872c-4f920f2609ad","ControlNumber":"9742","DisclosureBlock":"","End":"4\/10\/2022 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"21283","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"18","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Benedito Carneiro, MD;MS","PresenterKey":"51b3b939-e2b7-481f-ab16-ab2e5e8eb35a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Concluding Remarks","SearchResultFooter":"","SearchResultHeader":"Apr 10 2022  3:00PM","SessionId":"766","SessionOnDemand":"False","SessionTitle":"Biomarker Advances in Clinical Trials","ShowChatLink":"false","Start":"4\/10\/2022 4:50:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Concluding Remarks","Topics":null,"cSlideId":""}]